Search by Drug Name or NDC
NDC 57894-0469-01 TALVEY 3 mg/1.5mL Details
TALVEY 3 mg/1.5mL
TALVEY is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Janssen Biotech, Inc.. The primary component is TALQUETAMAB.
MedlinePlus Drug Summary
Talquetamab-tgvs is used to treat multiple myeloma (a type of cancer of the bone marrow) that has returned or that did not respond to at least 4 other treatments. Talquetamab-tgvs is in a class of medications called bispecific T-cell engager antibodies. It works by killing cancer cells.
Related Packages: 57894-0469-01Last Updated: 04/21/2024
MedLinePlus Full Drug Details: Talquetamab-tgvs
Product Information
| NDC | 57894-0469 |
|---|---|
| Product ID | 57894-469_0333c380-455e-03c1-e063-6394a90a998d |
| Associated GPIs | |
| GCN Sequence Number | 085143 |
| GCN Sequence Number Description | talquetamab-tgvs VIAL 3 MG/1.5ML SUBCUT |
| HIC3 | V1K |
| HIC3 Description | ANTINEOPLASTICS ANTIBODY/ANTIBODY-DRUG COMPLEXES |
| GCN | 53419 |
| HICL Sequence Number | 049135 |
| HICL Sequence Number Description | TALQUETAMAB-TGVS |
| Brand/Generic | Brand |
| Proprietary Name | TALVEY |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | talquetamab |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 3 |
| Active Ingredient Units | mg/1.5mL |
| Substance Name | TALQUETAMAB |
| Labeler Name | Janssen Biotech, Inc. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761342 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 57894-0469-01 (57894046901)
| NDC Package Code | 57894-469-01 |
|---|---|
| Billing NDC | 57894046901 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (57894-469-01) / 1.5 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2023-08-09 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |